COVID-19 continues to affect the healthcare economy, disrupting and changing patient care and creating uncertainty for insurers

In this whitepaper, we discuss our recent observations of how COVID-19 has impacted patients, providers and payers—and what that means for biopharmaceutical companies David Rees, Market Access Practice Leader, Herspiegel Consulting